BC Extra | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...
BC Extra | Oct 4, 2019
Company News

Management tracks: J&J hires Bayer’s Swanson; plus Torque, Dynavax, Pact, Deciphera, NextCure, Retrophin, Verve, Jnana and more

Johnson & Johnson (NYSE:JNJ) hired Jim Swanson as EVP and group chief information officer. He was CIO and head of digital transformation, crop science, at Bayer AG (Xetra:BAYN). Swanson replaces Stuart McGuigan, who left in...
BC Extra | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...
BC Extra | May 23, 2019
Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
BC Week In Review | Mar 22, 2019
Financial News

Dynavax commercializing Heplisav-B with $75M debt financing

To fund the commercialization of its Heplisav-B HBV vaccine, Dynavax announced March 18 it was drawing down a $75 million non-dilutive loan through an existing agreement with CRG Servicing LLC. Dynavax Technologies Corp. (NASDAQ:DVAX) drew...
BioCentury | Jan 5, 2019

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Jan 10, 2018
Company News

Dynavax launches Heplisav-B in the U.S.

Dynavax Technologies Corp. (NASDAQ:DVAX) launched Heplisav-B in the U.S. to prevent infection caused by all known subtypes of HBV in adults. Heplisav-B combines hepatitis B surface antigen (HBsAg) with a toll-like receptor 9 (TLR9) agonist....
BioCentury | Jan 9, 2018

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
BioCentury | Jan 6, 2018

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Nov 10, 2017
Clinical News

FDA approves Dynavax's HBV vaccine

FDA approved Heplisav-B from Dynavax Technologies Corp. (NASDAQ:DVAX) to prevent infection caused by all known subtypes of HBV in adults ages 18 and older. The company said Heplisav-B is the only two-dose HBV vaccine approved...
Items per page:
1 - 10 of 209